Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing medicines for the treatment of cystic fibrosis (CF). Its lead product candidate is galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trials. The company also has a pipeline including navocaftor (SION-3067), a potentiator that has completed Phase 2 trials; SION-109, an intracellular loop 4 directed CFTR corrector in Phase 1; SION-2851, a TMD1-directed CFTR corrector in Phase 1; SION-451, a nucleotide-binding domain 1 stabilizer in Phase 1; and SION-719, another nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trials. Sionna is dedicated to advancing novel therapies for CF patients.

Sionna Therapeutics trades on the NasdaqGM exchange under the ticker symbol SION. The company's stock is denominated in US dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, Sionna is subject to the reporting and governance standards of the US Securities and Exchange Commission. Investors can buy and sell shares of SION in USD through brokerage accounts that have access to the Nasdaq market.

Sionna Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing innovative medicines for cystic fibrosis, a genetic disorder that affects the lungs and other organs. Biotechnology companies like Sionna use biological processes and living organisms to create therapies, often targeting specific molecular pathways. Sionna's research centers on CFTR modulators, which aim to correct the underlying protein defect in cystic fibrosis.

Sionna Therapeutics is headquartered in Waltham, Massachusetts, United States. The company was incorporated in 2019 and was originally known as Sling Therapeutics, Inc. before rebranding to Sionna Therapeutics in July 2021. Its location in the Boston area places it within a major biotechnology hub, providing access to research talent and partnerships. The company's focus on cystic fibrosis treatments reflects its commitment to addressing a serious genetic disease with significant unmet medical need.

Sionna Therapeutics is a clinical-stage biopharmaceutical company that generates value by researching and developing novel medicines for cystic fibrosis. As it has not yet received regulatory approval for any of its product candidates, the company currently does not generate revenue from product sales. Instead, it relies on funding from investors, partnerships, and potentially grants to advance its pipeline. Sionna's portfolio includes multiple candidates targeting different aspects of CFTR dysfunction, such as correctors, potentiators, and stabilizers. If successful, these therapies could be commercialized directly or through licensing agreements, generating revenue from sales to patients and healthcare providers.